Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Mansoury F et al. | 2022 | intact cell/cell culture, human gastric adenocarcinoma (AGS) and human normal fibroblast (Hu02) cell lines | magnetic field, 50/60 Hz | - |
Manzella N et al. | 2015 | intact cell/cell culture, HuDe cells (human dermal fibroblasts) | magnetic field, 50/60 Hz | 0.1 mT |
Martínez MA et al. | 2021 | intact cell/cell culture, NB69 cells (human neuroblastoma cells) | 50/60 Hz, magnetic field | 100 µT |
Martínez MA et al. | 2022 | intact cell/cell culture, NB69 cells (human neuroblastoma cells) | 50/60 Hz, magnetic field | - |
Masiuk M et al. | 2008 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells), K-562 (chronic myelogenous leukemia) | magnetic field, 50/60 Hz | 10–20 mT |
Merla C et al. | 2019 | - | 50/60 Hz, magnetic field | - |
Miki H et al. | 1999 | isolated bio./chem. substance, DNA/RNA, HeLa nuclear extract (<i>in vitro</i> transcription system) | magnetic field, 50/60 Hz | 10–100 µT |
Miller SC et al. | 1999 | intact cell/cell culture, U937 (human leukemic monocyte cell line) | magnetic field, 50/60 Hz, power transmission line | 0.08–1.3 mT |
Miyakoshi J et al. | 1998 | intact cell/cell culture, CHO-K1 (Chinese hamster ovary K1) cells | magnetic field, 50/60 Hz, co-exposure | 5–400 mT |
Miyakoshi J et al. | 1996 | intact cell/cell culture, CHO (Chinese hamster ovary) cells | magnetic field, 50/60 Hz | 5 mT |
Miyata H et al. | 2015 | intact cell/cell culture, human umbilical vein endothelial cells (HUVEC) | magnetic field, 50/60 Hz | 100 µT |
Molaei S et al. | 2019 | animal, rat/Wistar albino, whole body | 50/60 Hz, magnetic field | 1–2,000 µT |
Moraveji M et al. | 2016 | intact cell/cell culture, human dermal papilla mesenchymal cells | magnetic field, signals/pulses, 50/60 Hz, co-exposure | 1 mT |
Moraveji M et al. | 2021 | intact cell/cell culture, rat adipose-derived mesenchymal stem cells | magnetic field, 50/60 Hz, signals/pulses, also other exposures without EMF, co-exposure | - |
Morehouse CA et al. | 2000 | intact cell/cell culture, Daudi (Burkitt's lymphoma cell line) cells | magnetic field, 50/60 Hz | 12.5–500 µT |
Mousavi M et al. | 2014 | intact cell/cell culture, MCF-7 cells (human breast cancer cell line) | magnetic field, 50/60 Hz, co-exposure | 0.04 T |
Mousavi Maleki NS et al. | 2022 | intact cell/cell culture, human adenocarcinoma gastric cancer cell line (AGS) | magnetic field, 50/60 Hz | - |
Mustafa E et al. | 2021 | intact cell/cell culture, murine FDC-P1 (factor-dependent continuous - Paterson 1) hematopoietic cells | magnetic field, 50/60 Hz, co-exposure | 200 µT |
Mustafa E et al. | 2022 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | 50/60 Hz, magnetic field | - |
Nakanishi R et al. | 2023 | intact cell/cell culture, C2C12 cells (undifferentiated mouse myoblasts), animal, C57BL/6 mouse | magnetic field, 50/60 Hz | - |
Nakasono S et al. | 2000 | bacterium, <i>Escherichia coli</i>/K12 | magnetic field, low frequency, 50/60 Hz, co-exposure | 7.8–14 mT |
Nakasono S et al. | 2003 | intact cell/cell culture, yeast (<i>Saccharomyces cerevisiae</i>) | magnetic field, 50/60 Hz | 10 mT |
Nasrabadi N et al. | 2018 | intact cell/cell culture, human retinal pigment epithelial cells | 50/60 Hz, signals/pulses, magnetic field | 1 mT |
Nie K et al. | 2003 | intact cell/cell culture, HL-60 cells (human acute myeloid leukaemia cell line), MCF-7 cells (breast cancer cell line), 3Y1 cells (rat fibroblast cells) | magnetic field, 50/60 Hz, shielding/field deprivation | 100 µT |
Ning J et al. | 1992 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells), Daudi (Burkitt's lymphoma cell line) cells and normal human lymphocytes | low frequency, signals/pulses, 50/60 Hz, magnetic field | 0.1 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.